

The Stock Exchange of Hong Kong Limited (the “Stock Exchange”) takes no responsibility for the contents of this announcement, makes no representation as to its accuracy or completeness and expressly disclaims any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



**UPDATE ON THE LATEST DEVELOPMENT OF THE PUBLICATION
OF
FINAL RESULTS FOR THE YEAR ENDED 31 MARCH 2008**

Summary

The Board would like to update the shareholders of the Company on the latest development of the publication of the Final Results.

Trading in the securities of the Company on the Stock Exchange was suspended with effect from 9:30 a.m. on 1 August 2008 at the request of the Company and will remain suspended until publication of the Final Results.

Reference is made to the announcement of the Company (together with its subsidiaries, the “**Group**”) dated 31 July 2008 regarding, among others, the delay in publication of the audited final results of the Group (the “**Final Results**”) for the year ended 31 March 2008.

The board of directors (the “**Board**”) of the Company wishes to update the shareholders of the Company on the latest development of the publication of the Final Results.

The auditors (the “**Auditors**”) of the Group are yet to complete the audit of the Final Results, the progress of which is mainly affected by the following factors:

- (1) certain accounting books and records of 深圳市華生元基因工程發展有限公司 (“**Shenzhen Watsin**”), one of the subsidiaries of the Group in the People’s Republic of China (the “**PRC**”), in respect of the period before the Group’s acquisition of Shenzhen Watsin on 22 August 2007 as required by the Auditors for performing their audit procedures to verify the opening balances of Shenzhen Watsin at 22 August 2007 are yet to be made available to the Auditors, the progress of which has been affected by the turnover of the accounting staff of Shenzhen Watsin; and

- (2) during the year under review, the Group entered into a significant number of contracts in its ordinary and usual course of business in respect of certain pharmaceutical research and technology platforms projects. Although the valuation/expert reports and some of the supporting documents required by the Auditors for performing their audit procedures have been supplied to the Auditors and given the technicality nature of these reports, additional time is required by the Auditors to review the reports and the supporting documents, consider the assumptions under which the valuations on the projects were made, summarize and analyse the data and information collected and seek independent consultation and advice from valuers and pharmaceutical experts. Further information and supporting documents may be required by the Auditors.

The Auditors estimate that, on a non-committal basis, an extra time of at least six weeks (commencing from the time when the Auditors consider the above matters are cleared) is required for completing and finalising their audit.

In light of the above audit progress and to cater for any contingencies, the Company is actively seeking ways and considering various options with a view to accelerating the audit progress and the publication of the Final Results.

Due to uncertainty of the timing for clearing the above matters, the date for re-convening the Board meeting to consider and approve the Final Results will be determined and announced by the Company on a later date.

The Board will keep the shareholders of the Company informed of any major new developments relating to the publication of the Final Results as and when appropriate.

Trading in the securities of the Company on the Stock Exchange was suspended with effect from 9:30 a.m. on 1 August 2008 at the request of the Company and will remain suspended until publication of the Final Results.

By Order of the Board
Uni-Bio Science Group Limited
Tong Kit Shing
Chairman

Hong Kong, 18 August 2008

** For identification purposes only*

As at the date of this announcement, the executive Directors are Mr. Tong Kit Shing (Chairman), Mr. Liu Guoyao and Mr. Cheng Wai Man; the independent non-executive Directors are Mr. Zhou Yaoming, Mr. Lin Jian and Mr. So Yin Wai.